Do SGLT2 inhibitors prevent atrial fibrillation in patients with cardiovascular disorders?
SGLT2 inhibitors appear to prevent atrial fibrillation in patients with HFrEF, but this benefit is not clearly seen in those with HFmrEF or HFpEF based on trial-level meta-analysis.
Sodium-glucose co-transporter 2 inhibitors prevent AF. Their protective effect was confirmed in the HFrEF subgroup, but not in RCTs recruiting patients with HFmrEF/HFpEF, possibly indicating a different pathophysiology leading to AF among these conditions. However, given the limitations of a trial-level analysis, these findings are exploratory, pending confirmation from patient-level data.
Fedele et al. (Wed,) studied this question.